Construction of roads to begin soon under Phase IV of PMGSY: Chouhan (See 'Corp Brief') SAKSHAM-3000 switch cum router with 25.6 Tera bit per second launched (See 'Corp Brief') IPR - Permanent injunction issued against Defendant, prohibiting him from using 'VIVO' mark or any similar marks that could cause confusion and prevent any misrepresentation: HC (See 'Legal Desk') APEDA organizes 'Indian Mango Mania 2025' in Abu Dhabi (See 'Corp Brief') IPR - Superlative injunction opens up additional route for plaintiffs to avail grant of real-time reliefs against infringing activities of 'rogue' defendants, irrespective of mode thereof: HC (See 'Legal Desk') Need of strengthening SHG-led FNHW interventions Stressed (See 'Corp Brief') Santosh Kumar Takhele takes addl charge as Regional Executive Director, NTPC (See 'Corp Brief') IPR - Franchise India can't be allowed to pass off their products as that of Rasna's, since it may confuse members of trade and also of general public involved: HC (See 'Legal Desk') Scindia interacts with Postal and Sorting Assistants for spirit of 'Dak Sewa, Jan Sewa' (See 'Corp Brief') ESIC launches SPREE 2025 to expand Social Security Coverage (See 'Corp Brief') FERA - No penalty can be levied if therre is no default in realization of export proceeds: SAFEMA (See 'Legal Desk') CCI again penalises Federation of Publishers' and Booksellers' Association (See 'Corp Brief') CCI approves acquisition of equity in NACL Industries by Coromandel International (See 'Corp Brief') Hardeep Puri highlights LPG Connections and Oil & Gas Reforms (See 'Corp Brief') Arbitration and Conciliation Act 1996 - 613-day delay in filing appeal can be condoned where no valid explanation is given for this inordinate delay: HC (See 'Legal Desk') CCI nod for investment by British International in ReNew Photovoltaics (See 'Corp Brief') CCI okays acquisition of shares of Billionbrains Garage Ventures by Viggo Investment (See 'Corp Brief') IBC - Request for timeline for disbursal of claim in form of query, rather than request for information u/s 2(f) of RTI Act, is not permitted: IBBI (See 'Legal Desk') Pondicherry Univ launches Governance Cell to inspire Next-Gen Public Leaders (See 'Corp Brief') MoS discusses Coastal Action Plan, Deep Ocean Prospects in Puducherry (See 'Corp Brief') IPR - Controller of Patents must clearly specify in hearing notice 'known substance' against which claimed invention of applicant is being assessed: HC (See 'Legal Desk') MoU signed to develop MY Bharat 2.0 Platform (See 'Corp Brief') 8th National Level Steering Committee meeting of Atal Bhujal Yojana held (See 'Corp Brief') SARFAESI - If borrowers have already availed remedy u/s 17 and secured creditor has no other alternative remedy, then creditor can avail remedy of petition under Article 227: HC (See 'Legal Desk') Centre issues Model Rules to States to aid Ease of Doing Business in Agroforestry (See 'Corp Brief') We have to make cycling trend in this modern generation: Mandaviya (See 'Corp Brief') Arbitration & Conciliation Act - Commercial Court not justified in refusing to release 25% of arbitral award to petitioner-company solely due to its change of name: HC (See 'Legal Desk') Sonowal hails Brahma Kumaris for 50 years of spiritual service and human upliftment (See 'Corp Brief') CEA organises All-India Electrical Safety awareness programme (See 'Corp Brief') SEBI - Delay in filing appeal not condonable where facts reflect that appellant was clearly aware of proceedings commenced by SEBI but did not prosecute appeal: SAT (See 'Legal Desk') Why Family Businesses in India Are Losing Their Own Bloodline (See CORP EINSICHT)

Print

MoS reaffirms India's commitment to global pharmaceutical standardization

Published: Feb 06, 2025

By TIOLCorplaws News Service

NEW DELHI, FEB 06, 2025: UNION Minister of State for Health and Family Welfare, Anupriya Patel delivered the keynote address at the 15th International Meeting of World Pharmacopoeias (IMWP), hosted by the Indian Pharmacopoeia Commission (IPC) under the aegis of the Ministry of Health and Family Welfare, Government of India, in collaboration with the World Health Organization (WHO), here today. The meeting brought together global pharmacopoeial leaders, regulatory authorities, and industry stakeholders to deliberate on key issues related to pharmaceutical standards and harmonization.

Addressing the gathering, Patel reaffirmed India's commitment to global pharmaceutical standardization and regulatory convergence. She highlighted India's role as the "Pharmacy of the World" and emphasized the importance of ensuring access to high-quality medicines globally. She stated that the IMWP serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization.

On this occasion, the Union Minister also released the IPC Newsletter 2024 and a special IPC video film, which showcase India's advancements in pharmacopoeial science and the Commission's efforts in ensuring high-quality pharmaceutical standards. The video film can be accessed at the following link: https://www.youtube.com/watch?v=MCdAZodvOSM .

Punya Salila Srivastava, Secretary, Ministry of Health and Family Welfare, underscored the significance of global partnerships in strengthening pharmaceutical quality standards. She reiterated India's efforts in aligning regulatory frameworks with international best practices and ensuring the availability of safe and effective medicines worldwide.

Dr. Rajeev Singh Raghuvanshi, Secretary-cum-Scientific Director, IPC, and Drugs Controller General (India), highlighted IPC's contributions in setting global benchmarks in pharmacopoeial science. He elaborated on IPC's initiatives, including the IP Online platform, which enhances accessibility and usability of Indian Pharmacopoeia standards. He emphasized the role of scientific advancements and regulatory cooperation in shaping global pharmaceutical standards.

Dr. Roderico H. Ofrin, WHO Representative to India, commended India's leadership in pharmacopoeial standard-setting and emphasized the importance of regulatory harmonization in ensuring patient safety and public health.

The 15th IMWP is set to facilitate discussions on key focus areas, including:

- Updates on recommendations from the 14th IMWP and review of progress on harmonization initiatives.

- Emerging issues in impurity assessment (Q3) and the implications of ICH Q6 guidelines on pharmacopoeial monograph specifications.

- Defining the IMWP Charter to establish a long-term governance structure for the forum.

- Enhancing collaboration among global pharmacopoeias and regulatory bodies, with updates from the Pharmacopoeial Discussion Group (PDG).

- Promotion of environmental sustainability in pharmacopoeial practices and pharmaceutical manufacturing standards.

- Finalization of reports for the 15th IMWP and preparatory discussions for the 16th IMWP.

The deliberations during the IMWP will reinforce the role of pharmacopoeias in ensuring the quality, safety, and efficacy of medicines. The outcomes of the meeting will guide future collaborations in standard-setting and regulatory harmonization.

The 15th IMWP, which commenced today, will conclude on 7th February 2025. The discussions held over these three days will set the stage for further strengthening global pharmacopoeial cooperation and enhancing pharmaceutical quality assurance.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.